Latest On IVERIC bio, Inc (ISEE):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-30 16:21 EST | News | Iveric bio, Still A 5+% Opportunity | N/A |  |
| 2023-05-23 13:53 EST | News | Bayer, Amgen looked at Iveric before agreeing to Astellas sale - report | N/A | |
| 2023-05-01 10:45 EST | News | IVERIC Bio jumps 18% on acquisition by Astellas Pharma | N/A | |
| 2023-04-30 23:01 EST | News | Astellas Pharma agrees to buy Iveric Bio for $5.9 billion | N/A | |
| 2023-03-23 20:31 EST | News | Iveric Bio: ACP Advances As GATHER Results Continue To Impress | N/A | |
About IVERIC bio, Inc (ISEE):
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 fo read more...r the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was incorporated in 2007 and is based in New York, New York.
General
- Name IVERIC bio, Inc
- Symbol ISEE
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 57
- Fiscal Year EndDecember
- IPO Date2013-09-25
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://ivericbio.com
Valuation
- Price/Book (Most Recent Quarter) 3.15
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.04
- Next Year EPS Estimate -$0.93
- Next Quarter EPS Estimate -$0.25
- Return on Assets -32%
- Return on Equity -55%
- Earnings Per Share $1.53
- Revenue Per Share $0
- Gross Profit -62784000
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 555.27 million
- EBITDA -58471000
- Analyst Target Price $13.33
- Book Value Per Share $2.13
Share Statistics
- Shares Outstanding 90.14 million
- Shares Float 63.72 million
- % Held by Insiders 65%
- % Held by Institutions 92.4%
- Shares Short 4.6 million
- Shares Short Prior Month 6.03 million
- Short Ratio 7.04
- Short % of Float 6%
- Short % of Shares Outstanding 5%
Technicals
- Beta 1.6
- 52 Week High $7.98
- 52 Week Low $2.8
- 50 Day Moving Average 6.05
- 200 Day Moving Average 6.08
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
IVERIC bio, Inc (ISEE) Dividend Calendar:
IVERIC bio, Inc (ISEE) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
IVERIC bio, Inc (ISEE) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
IVERIC bio, Inc (ISEE) Chart:
IVERIC bio, Inc (ISEE) News:
Below you will find a list of latest news for IVERIC bio, Inc (ISEE) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
IVERIC bio, Inc (ISEE) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ISEE Trades:
IVERIC bio, Inc (ISEE) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-03 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-02 | 8-K (Current report) | |
| 2020-10-28 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-09-24 | EFFECT (Notice of Effectiveness) | |
| 2020-09-18 | POS AM (Post-Effective amendments for registration statement) | |
| 2020-08-14 | 424B3 (Prospectus [Rule 424(b)(3)]) | |
| 2020-08-13 | EFFECT (Notice of Effectiveness) | |
| 2020-08-11 | UPLOAD (SEC-generated letter) | |
| 2020-08-11 | CORRESP (Correspondence) | |
| 2020-08-06 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-08-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-05 | 8-K (Current report) | |
| 2020-07-17 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-07-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-17 | 8-K (Current report) | |
| 2020-07-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-01 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-07-01 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-06-29 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-06-26 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
IVERIC bio, Inc (ISEE) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of IVERIC bio, Inc (ISEE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 65%
Institutional Ownership: 9240%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-07-01 | David Francis Carroll | SVP, CFO and Treasurer | Buy | 7,500.00 | 33,707.00 | | ||
| 2020-04-01 | GLENN SBLENDORIO | President and CEO | Buy | 18,750.00 | 225,061.00 | | ||
| 2020-01-06 | Keith Westby | SVP & COO | Sell | 293.00 | 8.07 | 2,364.51 | 40,983.00 | |
| 2020-01-06 | DAVID R GUYER | Executive Chairman | Sell | 3,367.00 | 8.07 | 27,171.69 | 53,972.00 | |
| 2020-01-04 | Keith Westby | SVP & COO | Buy | 700.00 | 41,276.00 | | ||
| 2020-01-04 | DAVID R GUYER | Executive Chairman | Buy | 6,250.00 | 57,339.00 | | ||
| 2019-12-13 | Keith Westby | SVP & COO | Sell | 4,530.00 | 6.60 | 29,898.00 | 40,576.00 | |
| 2019-12-13 | DAVID R GUYER | Executive Chairman | Sell | 9,275.00 | 6.60 | 61,215.00 | 51,089.00 | |
| 2019-12-12 | GLENN SBLENDORIO | President and CEO | Buy | 22,950.00 | 199,804.00 | | ||
| 2019-12-12 | David Francis Carroll | SVP, CFO and Treasurer | Buy | 12,500.00 | 26,207.00 | | ||
| 2019-12-12 | Keith Westby | SVP & COO | Buy | 12,500.00 | 45,106.00 | | ||
| 2019-12-12 | DAVID R GUYER | Executive Chairman | Buy | 17,200.00 | 60,364.00 | | ||
| 2019-12-10 | GLENN SBLENDORIO | President and CEO | Buy | 62,500.00 | 4.00 | 250,000.00 | 176,854.00 | |
| 2019-11-15 | GLENN SBLENDORIO | President and CEO | Buy | 15,000.00 | 3.12 | 46,851.00 | 114,354.00 | |
| 2019-07-02 | David Francis Carroll | SVP, CFO and Treasurer | Sell | 2,773.00 | 1.25 | 3,466.25 | 13,707.00 | |
| 2019-07-01 | David Francis Carroll | SVP, CFO and Treasurer | Buy | 7,500.00 | 16,480.00 | | ||
| 2019-05-10 | GLENN SBLENDORIO | President and CEO | Buy | 25,000.00 | 1.48 | 37,000.00 | 93,105.00 | |
| 2019-04-02 | GLENN SBLENDORIO | President and CEO | Sell | 6,914.00 | 1.43 | 9,887.02 | 68,105.00 | |
| 2019-04-01 | GLENN SBLENDORIO | President and CEO | Buy | 18,750.00 | 75,019.00 | | ||
| 2019-01-07 | Keith Westby | SVP & COO | Sell | 299.00 | 1.30 | 388.70 | 32,606.00 | |